{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:40:45Z","timestamp":1792856445241,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PHRT Personalized Health and Related Technologies","award":["PHRT-307"],"award-info":[{"award-number":["PHRT-307"]}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_188978"],"award-info":[{"award-number":["310030_188978"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["884104"],"award-info":[{"award-number":["884104"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gideon Foundation","award":["Gideon Foundation"],"award-info":[{"award-number":["Gideon Foundation"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological malignancies, primarily due to frequent late-stage diagnosis and the development of resistance to chemotherapy. The aim of this study was to evaluate the expression of tumor-associated targets in a large cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009179) of various EOC subtypes, represented on two tissue microarrays (TMAs), to support the future development of radionuclide therapies. The study primarily assessed folate receptor-alpha and -beta isoforms (FR\u03b1 and FR\u03b2), but also somatostatin receptor-2 (SSTR2), prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP), for which established radiopharmaceuticals already exist. Membranous expression of these targets on tumor cells was detected by immunohistochemistry using antibodies validated on xenografts with known target expression and semi-quantitatively evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Validation of the employed antibodies confirmed specific staining of the respective targets. The TMAs included tumors of high-grade and low-grade serous, endometrioid, clear cell, mucinous and carcinosarcoma. High FR\u03b1 expression was seen in several EOC histotypes, most frequently in high-grade serous (47%), while it was largely absent in mucinous EOC. The FR\u03b2 was expressed only in stromal cells. SSTR2 and PSMA were only present in 8% and 4% of the EOC cases and not associated to a specific subtype. FAP expression on tumor cells was found in 10% of all EOCs, while stromal FAP was seen in 47% of the cases, with the highest prevalence in high-grade serous EOC (42%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings of this study indicate that approved radionuclide therapies targeting SSTR2 or PSMA are unlikely to be suitable for treating EOC. In contrast, the frequent and high expression of FR\u03b1 in tumor cells and FAP in tumor-associated stromal cells suggests that FR\u03b1- and FAP-targeted radiopharmaceuticals hold promise for the treatment of advanced-stage EOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-025-01345-0","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:29:35Z","timestamp":1767025775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Benjamin D.","family":"Hunkeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Katrina","family":"Mapanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Choschzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7043-3456","authenticated-orcid":false,"given":"Niels J.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031845","author":"V Tavares","year":"2024","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, Medeiros R. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25031845.","journal-title":"Int J Mol Sci"},{"key":"1345_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20:820\u201342. https:\/\/doi.org\/10.1038\/s41571-023-00819-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1345_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, Version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:191\u2013226. https:\/\/doi.org\/10.6004\/jnccn.2021.0007.","journal-title":"J Natl Compr Canc Netw"},{"key":"1345_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","volume":"33","author":"FZ Nawaz","year":"2022","unstructured":"Nawaz FZ, Kipreos ET. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022;33:159\u201374. https:\/\/doi.org\/10.1016\/j.tem.2021.12.003.","journal-title":"Trends Endocrinol Metab"},{"key":"1345_CR5","doi-asserted-by":"publisher","first-page":"17442","DOI":"10.18632\/oncotarget.7856","volume":"7","author":"LS Boogerd","year":"2016","unstructured":"Boogerd LS, Boonstra MC, Beck AJ, Charehbili A, Hoogstins CE, Prevoo HA, et al. Concordance of folate receptor-\u03b1 expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients. Oncotarget. 2016;7:17442\u201354. https:\/\/doi.org\/10.18632\/oncotarget.7856.","journal-title":"Oncotarget"},{"key":"1345_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2193-1801-1-22","volume":"1","author":"DJ O\u2019Shannessy","year":"2012","unstructured":"O\u2019Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus. 2012;1:22. https:\/\/doi.org\/10.1186\/2193-1801-1-22.","journal-title":"Springerplus"},{"key":"1345_CR7","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/0006-2952(92)90089-2","volume":"44","author":"X Wang","year":"1992","unstructured":"Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol. 1992;44:1898\u2013901. https:\/\/doi.org\/10.1016\/0006-2952(92)90089-2.","journal-title":"Biochem Pharmacol"},{"key":"1345_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood-2008-04-150789","volume":"113","author":"W Xia","year":"2009","unstructured":"Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009;113:438\u201346. https:\/\/doi.org\/10.1182\/blood-2008-04-150789.","journal-title":"Blood"},{"key":"1345_CR9","doi-asserted-by":"publisher","first-page":"14700","DOI":"10.18632\/oncotarget.3739","volume":"6","author":"J Shen","year":"2015","unstructured":"Shen J, Putt KS, Visscher DW, Murphy L, Cohen C, Singhal S, et al. Assessment of folate receptor-beta expression in human neoplastic tissues. Oncotarget. 2015;6:14700\u20139. https:\/\/doi.org\/10.18632\/oncotarget.3739.","journal-title":"Oncotarget"},{"key":"1345_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101399","volume":"5","author":"X Bao","year":"2024","unstructured":"Bao X, Li Q, Chen D, Dai X, Liu C, Tian W, et al. A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. Cell Rep Med. 2024;5:101399. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101399.","journal-title":"Cell Rep Med"},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"R Nalio Ramos","year":"2022","unstructured":"Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Nunez NG, et al. Tissue-resident FOLR2\u2009+\u2009macrophages associate with CD8\u2009+\u2009T cell infiltration in human breast cancer. Cell. 2022;185:1189\u2013e20725. https:\/\/doi.org\/10.1016\/j.cell.2022.02.021.","journal-title":"Cell"},{"key":"1345_CR12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garcia Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389:2162\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2309169.","journal-title":"N Engl J Med"},{"key":"1345_CR13","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41:2436\u201345. https:\/\/doi.org\/10.1200\/JCO.22.01900.","journal-title":"J Clin Oncol"},{"key":"1345_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017.","journal-title":"Ann Oncol"},{"key":"1345_CR15","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","volume":"34","author":"I Vergote","year":"2016","unstructured":"Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, et al. A randomized, double-blind, placebo-controlled, Phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016;34:2271\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.63.2596.","journal-title":"J Clin Oncol"},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13550-020-00624-2","volume":"10","author":"S Gnesin","year":"2020","unstructured":"Gnesin S, M\u00fcller J, Burger IA, Meisel A, Siano M, Fruh M, et al. Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Res. 2020;10:32. https:\/\/doi.org\/10.1186\/s13550-020-00624-2.","journal-title":"EJNMMI Res"},{"key":"1345_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2967\/jnumed.113.133074","volume":"55","author":"AH Maurer","year":"2014","unstructured":"Maurer AH, Elsinga P, Fanti S, Nguyen B, Oyen WJ, Weber WA. Imaging the folate receptor on cancer cells with <inlineGraphic>Superscript<\/inlineGraphic>Tc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J Nucl Med. 2014;55:701\u20134. https:\/\/doi.org\/10.2967\/jnumed.113.133074.","journal-title":"J Nucl Med"},{"key":"1345_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091282","author":"C Bailly","year":"2019","unstructured":"Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, et al. Exploring tumor heterogeneity using PET imaging: the big picture. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091282.","journal-title":"Cancers (Basel)"},{"key":"1345_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s00259-020-04980-y","volume":"48","author":"P Guzik","year":"2021","unstructured":"Guzik P, Benesova M, Ratz M, Monne Rodriguez JM, Deberle LM, Schibli R, et al. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:972\u201383. https:\/\/doi.org\/10.1007\/s00259-020-04980-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1345_CR20","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. <Superscript>177<\/Superscript>Lu-dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"1345_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1345_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07103-7","author":"HH Tran","year":"2025","unstructured":"Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: a review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07103-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1345_CR23","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","volume":"87","author":"P Garin-Chesa","year":"1990","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235\u20139. https:\/\/doi.org\/10.1073\/pnas.87.18.7235.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1345_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ygyno.2025.01.010","volume":"193","author":"S Corvigno","year":"2025","unstructured":"Corvigno S, Fernebro J, Karlsson JS, Mezheieusky A, Martin-Bernabe A, De La Fuente LM, et al. High prevalence of FAP\u2009+\u2009cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density. Gynecol Oncol. 2025;193:148\u201355. https:\/\/doi.org\/10.1016\/j.ygyno.2025.01.010.","journal-title":"Gynecol Oncol"},{"key":"1345_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225744","author":"T Lindner","year":"2021","unstructured":"Lindner T, Giesel FL, Kratochwil C, Serfling SE. Radioligands targeting fibroblast activation protein (FAP). Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13225744.","journal-title":"Cancers (Basel)"},{"key":"1345_CR26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2967\/jnumed.120.255760","volume":"62","author":"P Guzik","year":"2021","unstructured":"Guzik P, Fang HY, Deberle LM, Benesova M, Cohrs S, Boss SD, et al. Identification of a PET Radiotracer for imaging of the folate receptor-alpha: A potential tool to select patients for targeted tumor therapy. J Nucl Med. 2021;62:1475\u201381. https:\/\/doi.org\/10.2967\/jnumed.120.255760.","journal-title":"J Nucl Med"},{"key":"1345_CR27","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1021\/jm8003366","volume":"51","author":"Y Deng","year":"2008","unstructured":"Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, et al. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. J Med Chem. 2008;51:5052\u201363. https:\/\/doi.org\/10.1021\/jm8003366.","journal-title":"J Med Chem"},{"key":"1345_CR28","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.7150\/thno.40482","volume":"10","author":"LM Deberle","year":"2020","unstructured":"Deberle LM, Benesova M, Umbricht CA, Borgna F, Buchler M, Zhernosekov K, et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10:1678\u201393. https:\/\/doi.org\/10.7150\/thno.40482.","journal-title":"Theranostics"},{"key":"1345_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10585-015-9723-4","volume":"32","author":"SK Baird","year":"2015","unstructured":"Baird SK, Allan L, Renner C, Scott FE, Scott AM. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. Clin Exp Metastasis. 2015;32:507\u201316. https:\/\/doi.org\/10.1007\/s10585-015-9723-4.","journal-title":"Clin Exp Metastasis"},{"key":"1345_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/his.14609","volume":"80","author":"WG McCluggage","year":"2022","unstructured":"McCluggage WG, Singh N, Gilks CB. Key changes to the world health organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80:762\u201378. https:\/\/doi.org\/10.1111\/his.14609.","journal-title":"Histopathology"},{"key":"1345_CR31","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0149-OA","author":"RL James","year":"2024","unstructured":"James RL, Sisserson T, Cai Z, Dumas ME, Inge LJ, Ranger-Moore J, et al. Development of an FR\u03b1 companion diagnostic immunohistochemical assay for mirvetuximab soravtansine. Arch Pathol Lab Med. 2024. https:\/\/doi.org\/10.5858\/arpa.2023-0149-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"1345_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216057","volume":"555","author":"RL Hollis","year":"2023","unstructured":"Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023;555:216057. https:\/\/doi.org\/10.1016\/j.canlet.2023.216057.","journal-title":"Cancer Lett"},{"key":"1345_CR33","doi-asserted-by":"publisher","first-page":"e2300393","DOI":"10.1200\/GO.23.00393","volume":"10","author":"M Wang","year":"2024","unstructured":"Wang M, Bi Y, Jin Y, Zheng ZJ. Global incidence of ovarian cancer according to histologic subtype: a population-based cancer registry study. JCO Glob Oncol. 2024;10:e2300393. https:\/\/doi.org\/10.1200\/GO.23.00393.","journal-title":"JCO Glob Oncol"},{"key":"1345_CR34","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/bjc.2014.567","volume":"111","author":"M Kobel","year":"2014","unstructured":"Kobel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study. Br J Cancer. 2014;111:2297\u2013307. https:\/\/doi.org\/10.1038\/bjc.2014.567.","journal-title":"Br J Cancer"},{"key":"1345_CR35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","volume":"108","author":"KR Kalli","year":"2008","unstructured":"Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619\u201326. https:\/\/doi.org\/10.1016\/j.ygyno.2007.11.020.","journal-title":"Gynecol Oncol"},{"key":"1345_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","volume":"191","author":"T Rushton","year":"2024","unstructured":"Rushton T, Krause HB, Samec T, Elliott A, Karnezis AN, Toboni MD, et al. Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma. Gynecol Oncol. 2024;191:80\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2024.09.021.","journal-title":"Gynecol Oncol"},{"key":"1345_CR37","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e74","author":"YY Leung","year":"2025","unstructured":"Leung YY, Llaurado-Fernandez M, Cameron A, Da-Anoy A, Cook LC, Hoenisch J, et al. Folr1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma. J Gynecol Oncol. 2025. https:\/\/doi.org\/10.3802\/jgo.2025.36.e74.","journal-title":"J Gynecol Oncol"},{"key":"1345_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/PGP.0000000000001053","volume":"44","author":"BC Lawson","year":"2025","unstructured":"Lawson BC, Marques-Piubelli ML, Westin SN, Malpica A. Folate receptor immunohistochemical staining and gynecologic tumors: initial experience with 216 cases. Int J Gynecol Pathol. 2025;44:167\u201373. https:\/\/doi.org\/10.1097\/PGP.0000000000001053.","journal-title":"Int J Gynecol Pathol"},{"key":"1345_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","volume":"188","author":"BL Manning-Geist","year":"2024","unstructured":"Manning-Geist BL, Sullivan MW, Zhou Q, Iasonos A, Selenica P, Stallworth C, et al. Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities. Gynecol Oncol. 2024;188:52\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.008.","journal-title":"Gynecol Oncol"},{"key":"1345_CR40","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2024-0210-OA","author":"E Deutschman","year":"2025","unstructured":"Deutschman E, Fulton R, Sloss CM. Evaluation of a laboratory-derived immunohistochemical assays for folate receptor alpha expression in epithelial ovarian cancer and comparison with a companion diagnostic. Arch Pathol Lab Med. 2025. https:\/\/doi.org\/10.5858\/arpa.2024-0210-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"1345_CR41","doi-asserted-by":"publisher","first-page":"e0135012","DOI":"10.1371\/journal.pone.0135012","volume":"10","author":"E de Boer","year":"2015","unstructured":"de Boer E, Crane LM, van Oosten M, van der Vegt B, van der Sluis T, Kooijman P, et al. Folate receptor-beta has limited value for fluorescent imaging in ovarian, breast and colorectal cancer. PLoS ONE. 2015;10:e0135012. https:\/\/doi.org\/10.1371\/journal.pone.0135012.","journal-title":"PLoS ONE"},{"issue":"1","key":"1345_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57841-x","volume":"10","author":"NJF Verweij","year":"2020","unstructured":"Verweij NJF, Yaqub M, Bruijnen STG, Pieplenbosch S, Ter Wee MM, Jansen G, et al. First in man study of [<Superscript>18<\/Superscript>F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. Sci Rep. 2020;10(1):1047. https:\/\/doi.org\/10.1038\/s41598-020-57841-x.","journal-title":"Sci Rep"},{"key":"1345_CR43","doi-asserted-by":"publisher","first-page":"108952","DOI":"10.1016\/j.nucmedbio.2024.108952","volume":"138\u2013139","author":"IA Ciggaar","year":"2024","unstructured":"Ciggaar IA, de Muynck L, de Geus-Oei LF, van Velden FHP, de Kroon CD, Pereira Arias-Bouda LM, et al. Preoperative [18F]fluoro-PEG-folate PET\/CT in advanced stage epithelial ovarian cancer: A safety and feasibility study. Nucl Med Biol. 2024;138\u2013139:108952. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108952.","journal-title":"Nucl Med Biol"},{"key":"1345_CR44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12149-015-1006-2","volume":"29","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Nakatani H, Yanaihara H, Omote M. Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults. Ann Nucl Med. 2015;29:792\u20138. https:\/\/doi.org\/10.1007\/s12149-015-1006-2.","journal-title":"Ann Nucl Med"},{"key":"1345_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13550-021-00756-z","volume":"11","author":"N Aide","year":"2021","unstructured":"Aide N, Poulain L, Elie N, Briand M, Giffard F, Blanc-Fournier C, et al. A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers. EJNMMI Res. 2021;11:11. https:\/\/doi.org\/10.1186\/s13550-021-00756-z.","journal-title":"EJNMMI Res"},{"key":"1345_CR46","doi-asserted-by":"publisher","first-page":"20857","DOI":"10.1038\/s41598-023-47877-0","volume":"13","author":"M Oron-Herman","year":"2023","unstructured":"Oron-Herman M, Kirmayer D, Lupp A, Schulz S, Kostenich G, Afargan M. Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach. Sci Rep. 2023;13:20857. https:\/\/doi.org\/10.1038\/s41598-023-47877-0.","journal-title":"Sci Rep"},{"key":"1345_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12307-014-0153-7","volume":"8","author":"P Mhawech-Fauceglia","year":"2015","unstructured":"Mhawech-Fauceglia P, Yan L, Sharifian M, Ren X, Liu S, Kim G, et al. Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer. Cancer Microenviron. 2015;8:23\u201331. https:\/\/doi.org\/10.1007\/s12307-014-0153-7.","journal-title":"Cancer Microenviron"},{"key":"1345_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2025.03.004","author":"Y Mori","year":"2025","unstructured":"Mori Y, Novruzov E, Giesel FL, Alavi A. Applications of fibroblast activation protein inhibitor-PET in interventional oncology. PET Clin. 2025. https:\/\/doi.org\/10.1016\/j.cpet.2025.03.004.","journal-title":"PET Clin"},{"key":"1345_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cpet.2023.03.005","volume":"18","author":"K Dendl","year":"2023","unstructured":"Dendl K, Koerber SA, Watabe T, Haberkorn U, Giesel FL. Current status of fibroblast activation protein imaging in gynecologic malignancy and breast cancer. PET Clin. 2023;18:345\u201351. https:\/\/doi.org\/10.1016\/j.cpet.2023.03.005.","journal-title":"PET Clin"},{"key":"1345_CR50","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"key":"1345_CR51","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00259-021-05634-3","volume":"49","author":"K Fu","year":"2022","unstructured":"Fu K, Pang Y, Zhao L, Lin L, Wu H, Sun L, et al. FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49:1767\u20139. https:\/\/doi.org\/10.1007\/s00259-021-05634-3.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01345-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:29:36Z","timestamp":1767025776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-025-01345-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01345-0","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the cantonal ethics committee Zurich, Switzerland (BASEC 2022\u2009\u2212\u200901778). For all patient tissue and data obtained before 2016, the ethics committee\u2019s approval functioned as a consent surrogate, substituting the requirement for written general consent. Studies were performed in accordance with the available licenses and ethical approval by the Swiss Cantonal Committee of Animal Experimentation (License: N\u00b0 75721 and 75668).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NJR discloses an advisory board function for AbbVie AG and receipt of a travel grant from Roche Diagnostics. CM, BDH and AKM disclose a collaboration with Merck & Cie KmG, Schaffhausen, Switzerland.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}